NASDAQ:SAGE Sage Therapeutics (SAGE) Stock Forecast, Price & News $59.54 +2.84 (+5.01%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$56.46▼$59.6850-Day Range$40.65▼$59.5452-Week Range$30.67▼$59.68Volume999,484 shsAverage Volume407,608 shsMarket Capitalization$3.56 billionP/E RatioN/ADividend YieldN/APrice Target$51.54 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Sage Therapeutics MarketRank™ ForecastAnalyst RatingHold2.27 Rating ScoreUpside/Downside13.4% Downside$51.54 Price TargetShort InterestBearish10.94% of Float Sold ShortDividend StrengthN/ASustainability-1.43Upright™ Environmental ScoreNews Sentiment1.11Based on 6 Articles This WeekInsider TradingAcquiring Shares$50,500 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($8.04) to ($8.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.38 out of 5 starsMedical Sector945th out of 988 stocksPharmaceutical Preparations Industry461st out of 477 stocks 1.1 Analyst's Opinion Consensus RatingSage Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 3 buy ratings, 8 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $51.54, Sage Therapeutics has a forecasted downside of 13.4% from its current price of $59.54.Amount of Analyst CoverageSage Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.94% of the float of Sage Therapeutics has been sold short.Short Interest Ratio / Days to CoverSage Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Sage Therapeutics has recently increased by 18.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSage Therapeutics does not currently pay a dividend.Dividend GrowthSage Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSage Therapeutics has received a 61.93% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Antidepressants" and "Clinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sage Therapeutics is -1.43. Previous Next 2.8 News and Social Media Coverage News SentimentSage Therapeutics has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Sage Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for SAGE on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Sage Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sage Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Sage Therapeutics is held by insiders.Percentage Held by Institutions85.60% of the stock of Sage Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Sage Therapeutics are expected to decrease in the coming year, from ($8.04) to ($8.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sage Therapeutics is -6.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sage Therapeutics is -6.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSage Therapeutics has a P/B Ratio of 2.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sage Therapeutics (NASDAQ:SAGE) StockSAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.Read More Receive SAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SAGE Stock News HeadlinesJune 10, 2023 | markets.businessinsider.comRBC Capital Sticks to Their Buy Rating for SAGE Therapeutics (SAGE)June 5, 2023 | finance.yahoo.comSage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare ConferenceJune 10, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 31, 2023 | finance.yahoo.com15 Most Suicidal States in AmericaMay 26, 2023 | americanbankingnews.comAnalysts Set Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target at $52.83May 25, 2023 | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) PT Raised to $61.00May 23, 2023 | msn.comB of A Securities Maintains Sage Therapeutics (SAGE) Buy RecommendationMay 23, 2023 | markets.businessinsider.comSAGE Therapeutics (SAGE) Receives a Buy from Bank of America SecuritiesJune 10, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 22, 2023 | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Coverage Initiated at StockNews.comMay 18, 2023 | finance.yahoo.comElizabeth Barrett At Sage Therapeutics Tops Up Holding By US$51k \May 15, 2023 | markets.businessinsider.comBank of America Securities Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)May 14, 2023 | americanbankingnews.comElizabeth Barrett Acquires 1,000 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) StockMay 11, 2023 | msn.comMorgan Stanley Maintains Sage Therapeutics (SAGE) Equal-Weight RecommendationMay 11, 2023 | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Upgraded to "Hold" at StockNews.comMay 9, 2023 | msn.comSage Therapeutics: Mid-2023 Data Readout And Possible FDA Approval Make This A Must WatchMay 9, 2023 | americanbankingnews.comFinancial Analysis: Sage Therapeutics (NASDAQ:SAGE) versus Mereo BioPharma Group (NASDAQ:MREO)May 7, 2023 | americanbankingnews.comWedbush Equities Analysts Increase Earnings Estimates for Sage Therapeutics, Inc. (NASDAQ:SAGE)May 7, 2023 | americanbankingnews.comAnalysts Offer Predictions for Sage Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:SAGE)May 6, 2023 | americanbankingnews.comRoyal Bank of Canada Increases Sage Therapeutics (NASDAQ:SAGE) Price Target to $63.00May 6, 2023 | americanbankingnews.comFY2026 EPS Estimates for Sage Therapeutics, Inc. (NASDAQ:SAGE) Reduced by HC WainwrightMay 6, 2023 | americanbankingnews.comHC Wainwright Equities Analysts Decrease Earnings Estimates for Sage Therapeutics, Inc. (NASDAQ:SAGE)May 5, 2023 | americanbankingnews.comSage Therapeutics, Inc. Expected to Post Q2 2023 Earnings of ($2.55) Per Share (NASDAQ:SAGE)May 5, 2023 | americanbankingnews.comSage Therapeutics, Inc. Forecasted to Earn Q2 2023 Earnings of ($2.54) Per Share (NASDAQ:SAGE)May 5, 2023 | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Rating Increased to Hold at StockNews.comMay 4, 2023 | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Lifted to Hold at StockNews.comMay 3, 2023 | msn.comCitigroup Maintains Sage Therapeutics (SAGE) Neutral RecommendationSee More Headlines SAGE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAGE Company Calendar Last Earnings5/02/2023Today6/09/2023Next Earnings (Estimated)8/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SAGE CUSIPN/A CIK1597553 Webwww.sagerx.com Phone(617) 299-8380Fax617-299-8379Employees471Year FoundedN/APrice Target and Rating Average Stock Price Forecast$51.54 High Stock Price Forecast$70.00 Low Stock Price Forecast$40.00 Forecasted Upside/Downside-13.4%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($9.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-532,780,000.00 Net Margins-5,932.09% Pretax Margin-5,932.09% Return on Equity-42.32% Return on Assets-39.37% Debt Debt-to-Equity RatioN/A Current Ratio14.21 Quick Ratio14.21 Sales & Book Value Annual Sales$7.69 million Price / Sales462.69 Cash FlowN/A Price / Cash FlowN/A Book Value$21.05 per share Price / Book2.83Miscellaneous Outstanding Shares59,760,000Free Float56,893,000Market Cap$3.56 billion OptionableOptionable Beta1.15 Key ExecutivesBarry E. GreenePresident, Chief Executive Officer & DirectorKimi E. IguchiChief Financial & Accounting OfficerAl RobichaudChief Scientific OfficerAmy SchacterleSenior VP-Research & Development StrategyMatt LasmanisChief Technology & Innovation OfficerKey CompetitorsAxsome TherapeuticsNASDAQ:AXSMZai LabNASDAQ:ZLABPTC TherapeuticsNASDAQ:PTCTImmunoGenNASDAQ:IMGNMaravai LifeSciencesNASDAQ:MRVIView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 1,978 shares on 6/1/2023Ownership: 0.023%ProShare Advisors LLCSold 1,353 shares on 5/26/2023Ownership: 0.017%Ameriprise Financial Inc.Bought 41,774 shares on 5/22/2023Ownership: 1.882%JPMorgan Chase & Co.Sold 37,513 shares on 5/18/2023Ownership: 2.301%New York State Common Retirement FundSold 10,907 shares on 5/18/2023Ownership: 0.047%View All Insider TransactionsView All Institutional Transactions SAGE Stock - Frequently Asked Questions Should I buy or sell Sage Therapeutics stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last twelve months. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares. View SAGE analyst ratings or view top-rated stocks. What is Sage Therapeutics' stock price forecast for 2023? 11 brokers have issued 1-year price targets for Sage Therapeutics' shares. Their SAGE share price forecasts range from $40.00 to $70.00. On average, they anticipate the company's share price to reach $51.54 in the next twelve months. This suggests that the stock has a possible downside of 13.4%. View analysts price targets for SAGE or view top-rated stocks among Wall Street analysts. How have SAGE shares performed in 2023? Sage Therapeutics' stock was trading at $38.14 at the beginning of the year. Since then, SAGE stock has increased by 56.1% and is now trading at $59.54. View the best growth stocks for 2023 here. When is Sage Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. View our SAGE earnings forecast. How were Sage Therapeutics' earnings last quarter? Sage Therapeutics, Inc. (NASDAQ:SAGE) announced its quarterly earnings data on Tuesday, May, 2nd. The biopharmaceutical company reported ($2.46) EPS for the quarter, topping analysts' consensus estimates of ($2.50) by $0.04. The biopharmaceutical company earned $3.30 million during the quarter, compared to analysts' expectations of $2.28 million. Sage Therapeutics had a negative net margin of 5,932.09% and a negative trailing twelve-month return on equity of 42.32%. The company's revenue for the quarter was up 120.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.07) earnings per share. What ETFs hold Sage Therapeutics' stock? ETFs with the largest weight of Sage Therapeutics (NASDAQ:SAGE) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Simplify Propel Opportunities ETF (SURI), Subversive Mental Health ETF (SANE), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal Healthcare Innovators ETF (BTEC). What other stocks do shareholders of Sage Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY). What is Sage Therapeutics' stock symbol? Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE." Who are Sage Therapeutics' major shareholders? Sage Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (11.85%), Wellington Management Group LLP (9.56%), BlackRock Inc. (8.25%), State Street Corp (4.58%), Price T Rowe Associates Inc. MD (3.19%) and Dimensional Fund Advisors LP (2.77%). Insiders that own company stock include Barry E Greene, Barry E Greene, Elizabeth Barrett, George Golumbeski, James M Frates and Jeffrey M Jonas. View institutional ownership trends. How do I buy shares of Sage Therapeutics? Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sage Therapeutics' stock price today? One share of SAGE stock can currently be purchased for approximately $59.54. How much money does Sage Therapeutics make? Sage Therapeutics (NASDAQ:SAGE) has a market capitalization of $3.56 billion and generates $7.69 million in revenue each year. The biopharmaceutical company earns $-532,780,000.00 in net income (profit) each year or ($9.37) on an earnings per share basis. How many employees does Sage Therapeutics have? The company employs 471 workers across the globe. How can I contact Sage Therapeutics? Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The official website for the company is www.sagerx.com. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at ir@sagerx.com, or via fax at 617-299-8379. This page (NASDAQ:SAGE) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.